Pasithea Therapeutics Corp. (KTTA) Institutional Ownership

Ownership Summary

Pasithea Therapeutics Corp. (NASDAQ:KTTA) appears in 25 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 173.2% of Pasithea Therapeutics's outstanding shares in December 2025, up from 7.8% in September 2025.
• Their total shares held in KTTA increased 2530.32% quarter over quarter, and separately, investors owning Pasithea Therapeutics increased 212.5% from a year ago.
• Among the 25 funds, 18 bought more Pasithea Therapeutics shares, 4 sold down, and 3 held their ground.
• Institutional investors collectively held 12.89Mn shares in Pasithea Therapeutics as of December 2025, up by 12.4Mn shares quarter on quarter, and up 12.81Mn shares year over year.
• As of December 31, 2025, the biggest holder of Pasithea Therapeutics is Janus Henderson Group Plc at 4.2Mn shares, representing 56.42% of shares outstanding.
• The largest buyers of Pasithea Therapeutics for the quarter ending December 2025 were Janus Henderson Group Plc (2.1Mn), Cable Car Capital, LP (706.38K), Stonepine Capital Management, LLC (556.24K), RENAISSANCE TECHNOLOGIES LLC (93.4K), VANGUARD CAPITAL MANAGEMENT LLC (53.82K).
• The largest sales of KTTA for the quarter ending December 2025 came from Ameriprise Financial Inc (579.23K), TWO SIGMA INVESTMENTS, LP (27.72K), Northern Trust Corp (8.72K), Tower Research Capital LLC (TRC) (1.09K).
• Per Business Quant, the top 10 investors in KTTA for the quarter ending December 2025 include Janus Henderson Group Plc (4.2Mn), Vivo Capital, LLC (2.1Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.1Mn), Squadron Capital Management LLC (2.1Mn), Ameriprise Financial Inc (1.35Mn), Cable Car Capital, LP (1.21Mn), Stonepine Capital Management, LLC (831.3K), AdvisorShares Investments LLC (337.51K), Persistent Asset Partners Ltd (290.56K), GEODE CAPITAL MANAGEMENT, LLC (103.98K).